Cited by 222Alzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalusBarrier Structure and Function Studies

The DOI matches its Crossref record.

Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries

Ghersi‐Egea, J.‐F., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., Fenstermacher, J. D.·1996·Journal of Neurochemistry

DOI 10.1046/j.1471-4159.1996.67020880.x

Open this paper in CoChat — free account

Abstract

In Alzheimer's disease, the neuritic or senile amyloid plaques in hippocampus and association cortex, the diffuse plaques in brain areas such as the cerebellum and sensorimotor cortex, and the amyloid deposits in the walls of pial and parenchymal blood vessels are mainly composed of amyloid beta-peptides. In the present study, either soluble 40-residue amyloid beta-peptide radiolabeled with 125I (I-sAbeta) or [14C]polyethylene glycol ([14C]PEG, a reference material) was briefly infused into one lateral ventricle of normal rats. By 3.5 min, 30% of the I-sAbeta was cleared from ventricular CSF into blood; another 30% was removed over the next 6.5 min. No [14C]PEG was lost from the CSF-brain system during the first 5 min, and only 20% was cleared by 10 min. Much of the I-sAbeta that reached the subarachnoid space was retained by pial arteries and arterioles. Virtually no I-sAbeta was found in brain. The clearance of amyloid beta-peptides from the CSF-brain system, reported herein for normal rats, may be reduced in Alzheimer's disease, thus contributing to amyloid deposition in cerebral tissue and blood vessels.

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.1996.67020880.x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 215

In situ processing and distribution of intracerebrally injected OVA in the CNS
Ling, C., Sándor, M., & Fábry, Z. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00249-2 · Cited by 66
Alzheimer's soluble amyloid β is a normal component of human urine
Ghiso, J. A., Calero, M., Matsubara, E., Governale, S., Chuba, J. V., Beavis, R. C., Wısnıewskı, T., & Frangione, B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00400-6 · Cited by 90
Self-citation
A Mathematical Model of the Impact of Novel Treatments on the AβBurden in the Alzheimer's Brain, CSF and Plasma
Craft, D. (2002) · Bulletin of Mathematical Biology · doi:10.1006/bulm.2002.0304 · Cited by 64
β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
Andreasen, N., & Blennow, K. (2002) · Peptides · doi:10.1016/s0196-9781(02)00056-6 · Cited by 86
In Vitro Evidence That β-Amyloid Peptide 1–40 Diffuses Across the Blood–Brain Barrier and Affects Its Permeability
Strazielle, N., Ghersi‐Egea, J., Ghiso, J. A., Dehouck, M., Frangione, B., Patlak, C. S., Fenstermacher, J. D., & Gorevic, P. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.1.29 · Cited by 60
“An impairment of sAb clearance from CSF (56, 57) and a decreased elimination of the peptide via normal drainage pathways of interstitial fluid (58) could result in increased sAb concentration around leptomeningeal vessels (24), or around parenchymal vessels that have patent perivascular spaces connected to the subarac…”
BackgroundSelf-citation
Cerebral clearance of human amyloid‐β peptide (1–40) across the blood–brain barrier is reduced by self‐aggregation and formation of low‐density lipoprotein receptor‐related protein‐1 ligand complexes
Ito, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85
Aβ42-induced Increase in Neprilysin Is Associated with Prevention of Amyloid Plaque Formation in Vivo
Mohajeri, M. H., Wollmer, M. A., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202899200 · Cited by 66
Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets
Zloković, B. V. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00150-3 · Cited by 63
Enhanced Proteolytic Clearance of Plasma Aβ by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain Aβ in Mice
Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., Peters, E. C., Urbina, H. D., Welzel, G., Althage, A., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3407-12.2013 · Cited by 59
“…have reported transport of A from the periphery into the brain (Zlokovic et al., 1993; Ghilardi et al., 1996; Poduslo et al., 1997; Mackic et al., 1998) and in the reverse direction, from the brain into the periphery (Ghersi-Egea et al., 1996; Shibata et al., 2000; Cirrito et al., 2005).”
Background
Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer
Petra, E. S. (2012) · Frontiers in bioscience · doi:10.2741/4035 · Cited by 68
“(49) From cell culture research it was inferred that Abeta can be absorbed from CSF at the choroid plexuses.”
Background
Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
“Although there is evidence that Ab transport at the blood-CSF barrier (choroid plexus) favors Ab clearance from the CSF, it is not sufficient to decrease Ab accumulation with age (Ghersi-Egea et al., 1996; Pascale et al., 2011; Silverberg et al., ssion at the BBB. Western blot OD 10.”
Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype
Tanskanen, M., Lindsberg, P. J., Tienari, P. J., Polvikoski, T. M., Sulkava, R. O., Verkkoniemi, A., Rastas, S., Paetau, A. E., & Kiuru‐Enari, S. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00652.x · Cited by 57
Antibody‐based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools
Lichtlen, P., & Mohajeri, M. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05064.x · Cited by 60
Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double Aß in human AßPP transgenic mice
Davis, J., Xu, F., Miao, J., Previti, M. L., Romanov, G. A., Ziegler, K., & Nostrand, W. E. V. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.031 · Cited by 58
Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.
Shoji, M. (2002) · Frontiers in Bioscience · doi:10.2741/shoji · Cited by 62
“Much of the infused Aβ that reached the subarachnoid space was retained by pial arteries and arteioles [11,56].”
Background
Detection of Apolipoprotein E/Dimeric Soluble Amyloid β Complexes in Alzheimer's Disease Brain Supernatants
Permanne, B., Perez, C., Soto, C., Frangione, B., & Wisniewski, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7727 · Cited by 49
Self-citation
The Concentration of Soluble Extracellular Amyloid-β Protein in Acute Brain Slices from CRND8 Mice
Waters, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015709 · Cited by 60
Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of 125I-Amyloid β Protein 40 in Wild-Type and Alzheimer’s Disease Transgenic Mice (APP,PS1) and Its Implications for Amyloid Plaque Formation
Kandimalla, K. K., Curran, G. L., Holasek, S. S., Gilles, E. J., Wengenack, T. M., & Poduslo, J. F. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081901 · Cited by 59
Amyloid‐β peptide(1‐40) elimination from cerebrospinal fluid involves low‐density lipoprotein receptor‐related protein 1 at the blood‐cerebrospinal fluid barrier
Fujiyoshi, M., Tachikawa, M., Ohtsuki, S., Ito, S., Uchida, Y., Akanuma, S., Kamiie, J., Hashimoto, T., Hosoya, K., Iwatsubo, T., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07311.x · Cited by 63
Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
Nutu, M., Zetterberg, H., Londos, E., Minthon, L., Nägga, K., Blennow, K., Hansson, O., & Öhrfelt, A. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353442 · Cited by 57
Permeability of the mouse blood-brain barrier to murine interleukin-2: predominance of a saturable efflux system.
Banks, W., Niehoff, M., & Zalcman, S. (2004) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2003.09.013 · Cited by 54
Alzheimer’s disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs
Zolezzi, J. M., Candia, S. B., Santos, M. J., & Inestrosa, N. C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00176 · Cited by 56
“This situation is most relevant for final Aβ elimination, a process that primarily occurs in the liver (Ghiso et al., 2004; Tamaki et al., 2006; Sagare et al., 2012), and to a lesser extent, in the kidneys (Ghersi-Egea et al., 1996; Sagare et al., 2007; Figure 3).”
Background
Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease.
Zhang, Q., Yu, J.-T., Zhu, Q.-X., Zhang, W., Wu, Z.-C., Miao, D., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.018 · Cited by 53
Lack of brain‐to‐blood efflux transport activity of low‐density lipoprotein receptor‐related protein‐1 (LRP‐1) for amyloid‐β peptide(1–40) in mouse: involvement of an LRP‐1‐independent pathway
Ito, S., Ueno, T., Ohtsuki, S., & Terasaki, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06708.x · Cited by 48
Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease
Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00158-8 · Cited by 64
Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study
Hilal, S., Wolters, F. J., Verbeek, M. M., Vanderstichele, H., Ikram, M. K., Stoops, E., Ikram, M. A., & Vernooij, M. W. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0395-6 · Cited by 55
Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging
Zhang, W., Xiong, H., Callaghan, D., Liu, H., Jones, A., Pei, K., Fatehi, D., Brunette, E., & Stanimirovic, D. B. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-13 · Cited by 43
“Aβ brain intake and brain clearance have been studied using radioisotope-labeled Aβ peptides injected systemically or stereotactically into the brain, and by monitoring their appearance in various compartments, including cerebral spinal fluid (CSF) [21].”
Background
The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans
Mehta, N. H., Sherbansky, J., Kamer, A. R., Carare, R. O., Butler, T., Rusinek, H., Chiang, G. C.-Y., Li, Y., Strauß, S., Saint-Louis, L. A., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.769948 · Cited by 58
β -Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain A β Levels in APPswe/PS1ΔE9 Mice, as Detected by SELDI-TOF-Based ProteinChip ® Technology
Vehmas, A. K., Borchelt, D., Price, D. L., McCarthy, D. B., Wills-Karp, M. A., Peper, M. J., Rudow, G. L., Luyinbazi, J., Siew, L. T., & Troncoso, J. C. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717578 · Cited by 43
Advances in Amyloid-β Clearance in the Brain and Periphery: Implications for Neurodegenerative Diseases
Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 51
“Amyloid-β has also been detected in human urine samples [294], and animal experiments have shown that the kidney filtration removes amyloid-β from the blood into the urine [232, 295].”
Background
Apolipoprotein E Dose-Dependent Modulation of β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease
DeMattos, R. B. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:255 · Cited by 55
Quantifying cerebrospinal fluid dynamics: A review of human neuroimaging contributions to CSF physiology and neurodegenerative disease
Mehta, N. H., Suss, R. A., Dyke, J. P., Theise, N. D., Chiang, G. C.-Y., Strauß, S., Saint-Louis, L. A., Li, Y., Pahlajani, S. S., Babaria, V., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105776 · Cited by 51
“Accordingly, the CSF circulation significantly modulates the removal of toxic metabolites and metabolic byproducts, in order to maintain physiological homeostasis of the brain (Rennels et al., 1985; Ghersi-Egea et al., 1996; Bakker et al., 2016; Benveniste et al., 2017)”
Background
In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein
McIntee, F. L., Giannoni, P., Blais, S. P., Sommer, G., Neubert, T. A., Rostagno, A. A., & Ghiso, J. A. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00223 · Cited by 42
“…Aβ clearance data have been generated with monomeric Aβ species or with peptides with poorly characterized aggregation state (Zlokovic et al., 1993; Ghersi-Egea et al., 1996; Martel et al., 1997; Mackic et al., 1998; Poduslo et al., 1999; Shibata et al., 2000; Strazielle et al., 2000; Bading et…”
Self-citation
A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly
Chouraki, V. A., de Bruijn, R. F. A. G., Chapuis, J., Bis, J. C., Reitz, C., Schraen‐Maschke, S., Ibrahim‐Verbaas, C. A., Grenier‐Boley, B., Delay, C., Rogers, R. S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.185 · Cited by 41
Possible Link between Lipid Metabolism and Cerebral Amyloid Angiopathy in Alzheimer’s Disease: A Role for High-Density Lipoproteins?
Mulder, M., & Terwel, D. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022429 · Cited by 40
α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects
Daniele, S., Pietrobono, D., Fusi, J., Iofrida, C., Chico, L., Petrozzi, L., Gerfo, A. L., Baldacci, F., Galetta, F., Siciliano, G., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0523-5 · Cited by 41
Laminin blocks the assembly of wild-type Aβ and the Dutch variant peptide into Alzheimer's fibrils
Bronfman, F. C., Alvarez, A. R., Morgan, C., & Inestrosa, N. C. (1998) · Amyloid · doi:10.3109/13506129809007285 · Cited by 37
Can Blood–Brain Barrier Play a Role in the Development of Cerebral Amyloidosis and Alzheimer's Disease Pathology
Zloković, B. V. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0134 · Cited by 36
Recent Insights on Alzheimer’s Disease Originating from Yeast Models
Seynnaeve, D., Vecchio, M. D., Fruhmann, G., Verelst, J., Cools, M., Beckers, J., Mulvihill, D. P., Winderickx, J., & Franssens, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071947 · Cited by 39
Antibody modified-silver nanoparticles for colorimetric immuno sensing of Aβ(1–40/1–42) based on the interaction between β-amyloid and Cu2+
Hu, T., Chen, C., Huang, G., & Yang, X. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.04.159 · Cited by 40
Possible Reverse Transport of β-Amyloid Peptide Across the Blood-Brain Barrier
Pluta, R. M., Misicka, A., Barcikowska, M., Spisacka, S., Lipkowski, A. W., & Januszewski, S. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6346-7_15 · Cited by 36
Brain leukocyte infiltration initiated by peripheral inflammation or experimental autoimmune encephalomyelitis occurs through pathways connected to the CSF-filled compartments of the forebrain and midbrain
Schmitt, C., Strazielle, N., & Ghersi‐Egea, J. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-187 · Cited by 122
“A large part of CSF is contained in the cisterns of the forebrain and midbrain, which connect to the third and mesencephalic ventricles via the different velae [12-14].”
Self-citation
Impairments in Brain-to-Blood Transport of Amyloid-β and Reabsorption of Cerebrospinal Fluid in an Animal Model of Alzheimer's Disease are Reversed by Antisense Directed Against Amyloid-β Protein Precursor
Banks, W. A., Kumar, V. B., Farr, S. A., Nakaoke, R., Robinson, S. M., & Morley, J. E. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100021 · Cited by 35
“A␤ is cleared from brain by saturable and nonsaturable mechanisms [5] [6] [7] [8] [9] [10] [11].”
Cerebral Amyloid Angiopathy in Alzheimer’s Disease and Related Disorders
Verbeek, M., de Waal, R., & Vinters, H. (2000) · Springer Netherlands · doi:10.1007/978-94-017-1007-7 · Cited by 33
Serum Amyloid-Beta Levels are Increased in Patients with Chronic Obstructive Pulmonary Disease
Bu, X.-L., Cao, G., Shen, L.-L., Xiang, Y., Jiao, S., Liu, Y.-H., Zhu, C., Zeng, F., Wang, Q.-H., Wang, Y.-R., et al. (2015) · Neurotoxicity research · doi:10.1007/s12640-015-9552-x · Cited by 30
“(Ghersi-Egea et al. 1996; Roberts et al. 2014), so the higher serum Ab levels might represent a higher Ab burden in brain.”
Background
Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood
Lönneborg, A. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256296 · Cited by 33
Obstructive sleep apnea may increase the risk of Alzheimer's disease
Przybylska-Kuć, S., Zakrzewski, M., Dybała, A., Kiciński, P., Dzida, G., Myśliński, W., Prystupa, A., Mosiewicz-Madejska, B., & Mosiewicz, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221255 · Cited by 29
The rapid flow of cerebrospinal fluid from ventricles to cisterns via subarachnoid velae in the normal rat.
Fenstermacher, J., Ghersi-Egea, J., Finnegan, W., & Chen, J. (1997) · Acta neurochirurgica. Supplement · doi:10.1007/978-3-7091-6837-0_88 · Cited by 29
Self-citation
Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
Xie, H., Chung, J.-K., Mascelli, M. A., & McCauley, T. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122453 · Cited by 30
“Studies of other enzymes administered directly to the CNS demonstrate rapid clearance from the CSF [9,10].”
Background
Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins
Banks, W. A., Pagliari, P., Nakaoke, R., & Morley, J. E. (2004) · Peptides · doi:10.1016/j.peptides.2004.09.016 · Cited by 26
Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness
Shoji, M., & Kanai, M. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3306 · Cited by 31
Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System
Tan, J. Y., Sellers, D. L., Pham, B., Pun, S. H., & Horner, P. J. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00108 · Cited by 34
“Once in the parenchyma, therapeutics have variable degrees of diffusion and entrapment that can be modeled based on protein or drug size and composition (Patlak et al., 1983; Ghersi-Egea et al., 2002; Hrabe et al., 2004; Nicholson et al., 2011).”
Background
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis
Carter, T. L., Pedrini, S., Ghiso, J. A., Ehrlich, M. E., & Gandy, S. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.09.022 · Cited by 26
Self-citation
Determination of guinea-pig cortical γ-secretase activity ex vivo following the systemic administration of a γ-secretase inhibitor
Grimwood, S., Hogg, J. E., Jay, M. T., Lad, A. M., Lee, V. S., Murray, F., Peachey, J., Townend, T., Vithlani, M., Beher, D., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.01.016 · Cited by 25
Progress Towards a Consensus on Biomarkers for Alzheimer‘S Disease: A Review of Peripheral Analytes
Rembach, A., Ryan, T. M., Roberts, B. R., Doecke, J. D., Wilson, W. J., Watt, A. D., Barnham, K. J., & Masters, C. L. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.59 · Cited by 18
Cerebrospinal Fluid β-Amyloid Turnover in the Mouse, Dog, Monkey and Human Evaluated by Systematic Quantitative Analyses
Lu, Y., Barton, H. A., Leung, L. Y., Zhang, L., Hajós‐Korcsok, É., Nolan, C. E., Liu, J., Becker, S. L., Wood, K. M., Robshaw, A., et al. (2012) · Neurodegenerative Diseases · doi:10.1159/000341217 · Cited by 20
Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's Disease
Montalto, M., Farrar, G., & Hehir, C. A. T. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.023 · Cited by 22
Aβ immunization: Moving Aβ peptide from brain to blood
Lee, V. M. ‐. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171311798 · Cited by 23
Changes in the cerebrospinal fluid circulatory system of the developing rat: quantitative volumetric analysis and effect on blood-CSF permeability interpretation
Ghersi-Egea, J., Babikian, A., Blondel, S., & Strazielle, N. (2015) · Fluids and Barriers of the CNS · doi:10.1186/s12987-015-0001-2 · Cited by 20
“Histological images of all the CSF spaces analyzed in this paper can be found in previous publications for the adult rat [3,8,19].”
Self-citation
Current strategies for therapeutic drug delivery after traumatic CNS injury.
Lee, H. J., Ryu, J., & Vig, P. J. (2019) · Therapeutic delivery · doi:10.4155/tde-2019-0006 · Cited by 19
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer’s Disease?1
Kuhn, A. J., & Raskatov, J. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191201 · Cited by 31
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
Moreth, J., Mavoungou, C., & Schindowski, K. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00025 · Cited by 15
Mouse models of neurological disorders: A view from the blood–brain barrier
Banks, W. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.011 · Cited by 22
Low levels of amyloid-beta and its transporters in neonatal rats with and without hydrocephalus
Deren, K. E., Forsyth, J., Abdullah, O., Hsu, E. W., Klinge, P. M., Silverberg, G. D., Johanson, C. E., & McAllister, J. P. (2009) · Cerebrospinal Fluid Research · doi:10.1186/1743-8454-6-4 · Cited by 19
“In any case, the resulting reduced CSF flow diminishes the natural CSF function of maintaining homeostasis and leads to various neurological deficits [2- 7]. Interruption in normal CSF flow pathways create a deficiency in the ability of the CSF to clear toxic substances from the brain[8, 9 ].”
Background
Gut Microbiota and Immunotherapy for Alzheimer’s Disease
Dai, C., Liu, F., Iqbal, K., & Gong, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315230 · Cited by 22
TREM1: A Potential Therapeutic Target For Alzheimer’s Disease
Saadipour, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9716-y · Cited by 25
“2000) and clearance (Ghersi-Egea et al. 1996; Shibata et al. 2000) influence AD progression.”
Background
Interaction between Alzheimer's Amyloid-β and Amyloid-β-Metal Complexes with Cell Membranes
Suwalsky, M., Bolognin, S., & Zatta, P. F. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1032 · Cited by 16
“Aβ is quickly cleared from the cerebrospinal fluid into the bloodstream [43], but in AD brain patients, the level of Aβ remains particularly elevated [44].”
Novel ventriculoperitoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers
Silverberg, G. D., Mayo, M. R., Saul, T., Carvalho, J., & McGuire, D. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.1.97 · Cited by 18
An amylin analog used as a challenge test for Alzheimer's disease
Zhu, H., Stern, R. A., Tao, Q., Bourlas, A. P., Essis, M. D., Chivukula, M., Rosenzweig, J. L., Steenkamp, D., Xia, W., Mercier, G., et al. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.002 · Cited by 19
Role of A β Transport and Clearance in the Pathogenesis and Treatment of Alzheimer’s Disease
Holtzman, D. M., & Zloković, B. V. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_11 · Cited by 15
Interactions Between Apo E and Amyloid Beta and their Relationship to Nutriproteomics and Neurodegeneration
Martins, I. J., Gupta, V. B., Wilson, A. C., Fuller, S. J., & Martins, R. N. (2014) · Current Proteomics · doi:10.2174/157016461103140922163729 · Cited by 7
Reduced estimated glomerular filtration rate in Alzheimer's disease
Kerr, E., Craig, D., McGuinness, B., Dynan, K., Fogarty, D. G., Johnston, J. A., & Passmore, A. P. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2197 · Cited by 12
“Renal clearance has also been identified as another elimination pathway with rat studies showing high urinary levels of radioactive tracer after infusion of radio labelled Ab into the lateral ventricles (Ghersi-Egea et al., 1996).”
Background
Plasma amyloid-β, Aβ1-42, load is reduced by haemodialysis
Rubio, I., Caramelo, C. A., Gil, A., López, M. D., & de Yébenes, J. G. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10413 · Cited by 13
Systematic review of amyloid-beta clearance proteins from the brain to the periphery: implications for Alzheimer’s disease diagnosis and therapeutic targets
Huang, L., Liu, M., Li, Z., Li, B., Wang, J., & Zhang, K. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00865 · Cited by 13
“These findings suggest that Aβ can be filtered by the kidney from the blood to the urine as a physiological clearance pathway (Ghersi-Egea et al., 1996; Xiang et al., 2015).”
Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies
Zaghmi, A., Drouin‐Ouellet, J., Brambilla, D., & Gauthier, M. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120461 · Cited by 17
Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 12
Deposits of fibrillar A? do not cause neuronal loss or ferritin expression in adult rat brain
Bishop, G. M., & Robinson, S. R. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0796-2 · Cited by 11
“Indeed, A injected into the ventricles of rats is rapidly cleared from the cerebrospinal fluid into the blood (Ghersi-Egea et al., 1996).”
Background
Immunization for Alzheimer's disease
Sigurdsson, E. M., Frangione, B., & Wısnıewskı, T. (2002) · Drug Development Research · doi:10.1002/ddr.10068 · Cited by 14
“, 1990] and numerous studies have shown that Ab1-40/42 bidirectionally crosses the BBB in experimental animals [Ghersi-Egea et al., 1996; Ji et al., 2001; Mackic et al., 1998; Maness et al., 1994; Martel et al., 1996; Poduslo et al., 1997, 1999; Shibata et al., 2000; Zlokovic et al., 1993].”
InfluentialSelf-citation
The Choroid Plexus and Cerebrospinal Fluid System: Roles in Neurodegenerative Diseases
Badaut, J., & Ghersi‐Egea, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801740-1.00008-1 · Cited by 3
Self-citation
House dust mite-induced asthma exacerbates Alzheimer’s disease changes in the brain of the AppNL-G-F mouse model of disease
Sahu, B., Nookala, S., Floden, A. M., Ambhore, N. S., Sathish, V., Klug, M. G., & Combs, C. K. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.038 · Cited by 7
Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice
Duong, Q.-V., Kintzing, M. L., Kintzing, W. E., Abdallah, I. M., Brannen, A. D., & Kaddoumi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061489 · Cited by 6
“One of the important functions of the BBB is the clearance of amyloid-β (Aβ) from the brain [9].”
Background
The Blood-Brain Barriers
Banks, W. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_2 · Cited by 3
Association between idiopathic normal pressure hydrocephalus and Alzheimer's disease: a bidirectional Mendelian randomization study
Hu, Y., Cao, C., Li, M., He, H., Luo, L., & Guo, Y. Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-72559-w · Cited by 7
Role of Human Serum Albumin in the Prevention and Treatment of Alzheimer’s Disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2024) · Biology Bulletin Reviews · doi:10.1134/s2079086424010109 · Cited by 8
Modulating Role of TTR in Aβ Toxicity, from Health to Disease
Cardoso, I., Santos, L. M., & Alemi, M. (2016) · InTech eBooks · doi:10.5772/63194 · Cited by 7
“5 min post-infusion of radiolabelled Aβ into the lateral ventricle, 40% of the injected radioactivity was already in the blood and urine, and internalized by the liver and the kidneys, indicating not only a quick clearance mechanism but also the involvement of systemic organs in the elimination and catabolism of Aβ [2…”
Carotid dissection causing occipital lobe infarction
Cucchiara, B. L., & Kasner, S. E. (2005) · Neurology · doi:10.1212/01.wnl.0000182292.29000.74 · Cited by 6
Human Amyloid-β40 Kinetics after Intravenous and Intracerebroventricular Injections and Calcitriol Treatment in Rats In Vivo
Peng, H., Noh, K., Pan, S. R., Saldivia, V., Serson, S., Toscan, A., de Lannoy, I. A. M., & Pang, K. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090886 · Cited by 8
Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer’s Disease
Tao, Q., Zhu, H., Chen, X., Stern, R. A., Kowall, N. W., Au, R., Blusztajn, J. K., & Qiu, W. Q. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170948 · Cited by 6
“For example, although plasma Aβ levels are significantly different between AD and controls when a large sample size is used [26, 27], the sensitivity and specificity of these differences are too low to be useful as AD diagnostics [28] [29, 30].”
A Surgical Method to Improve the Homeostasis of CSF for the Treatment of Alzheimer’s Disease
Qin, Y., & Gu, J. W. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00261 · Cited by 5
The quest for a better insight into physiology of fluids and barriers of the brain: the exemplary career of Joseph D. Fenstermacher
Chodobski, A., Ghersi‐Egea, J., Nicholson, C., Nagaraja, T. N., & Szmydynger‐Chodobska, J. (2015) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-12-1 · Cited by 7
“(adapted with permission from [48]).”
MethodSelf-citation
Importance of Peptide Transporter 2 on the Cerebrospinal Fluid Efflux Kinetics of Glycylsarcosine Characterized by Nonlinear Mixed Effects Modeling
Huh, Y., Hynes, S., Smith, D. E., & Feng, M. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0980-0 · Cited by 5
“subependymal tissue, leptomeninges, outerlayers of pial vessels, and perivascular spaces (4,5).”
Aging of the Choroid Plexus and CSF System: Implications for Neurodegeneration
Preston, J., Wilson, M. R., & Chen, R.-L. (2005) · doi:10.1201/9781420023404.ch14 · Cited by 5
Antiaging methods and medicines for the memory
Banks, W. A., & Farr, S. A. (2004) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2004.02.007 · Cited by 5
A chemically modified preparation of α2‐macroglobulin binds β‐amyloid peptide with increased affinity and inhibits Aβ cytotoxicity
Mettenburg, J., Arandjelovic, S., & Gonias, S. L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02995.x · Cited by 3
Anatomy and Physiology of Cerebrospinal Fluid Dynamics
Martin, B. A., & Pahlavian, S. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813997-4.00005-0 · Cited by 15
Immunization Against Alzheimer’s Disease and Other Neurodegenerative Disorders
Selkoe, D., & Christen, Y. (2003) · Research and Perspectives in Alzheimer’s Disease · doi:10.1007/978-3-642-59332-1 · Cited by 4
Neuropathology of Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type
Maat–Schieman, M. L. C., van Duinen, S. G., Natté, R., & Roos, R. A. C. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_13 · Cited by 2
Synthesized boron compounds: Neurotoxic and oxidative effects in an in vitro model of Alzheimer's disease
Bayıl, S., Tozlu, Ö. Ö., & Karagul, B. (2025) · Science in progress · doi:10.1177/00368504251384830 · Cited by 3
Prevention of cerebral vasospasm by local delivery of cromakalim with a biodegradable controlled-release system in a rat model of subarachnoid hemorrhage.
Omeis, I., Chen, W., Jhanwar-Uniyal, M., Rozental, R., Murali, R., & Abrahams, J. (2009) · Journal of Neurosurgery · doi:10.3171/2008.8.jns08202 · Cited by 3
Apolipoproteins in Different Amyloidoses
Sadowski, M., & Wısnıewskı, T. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_6 · Cited by 3

Authors: Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D.
Affiliations: Stony Brook University (US)
NYU Langone Health (US)
Henry Ford Hospital (US)
Corresponding author: Fenstermacher, J. D.
ORCID: Ghersi‐Egea, J.‐F.
Ghiso, J.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 1996-08
Volume: 67
Issue: 2
Pages: 880-883
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1046/j.1471-4159.1996.67020880.x
OpenAlex: W2065410730
Cited by: 222
References: 0
Citations by year: 2025: 3 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 9 · 2014: 8 · 2013: 8 · 2012: 7
FWCI: 3.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2305 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
National Institutes of Health (5r01ns026004-05, 5r29ag010593-05)
National Institute on Aging (AG10593, AG05891)
National Institute of Neurological Disorders and Stroke (NS-26004)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords: amyloid-beta, cerebrospinal fluid, blood-CSF barrier, cerebral arteries, pial arteries, amyloid deposition, Alzheimer's disease, subarachnoid space
MeSH terms: Animals, Cerebral Arteries, Humans, Male, Metabolic Clearance Rate, Peptide Fragments, Amyloid beta-Peptides, Rats, Sprague-Dawley, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Metadata

Record

About these checks